Phase 2 Advanced Solid Tumors Clinical Trials

19 recruitingPhase 2

What is a Phase 2 trial?

Phase 2 trials evaluate whether a treatment works for a specific condition and further assess its safety. These studies typically enroll several hundred participants and provide preliminary data on effectiveness.

Showing 119 of 19 trials

Recruiting
Phase 1Phase 2

Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

Advanced Breast CancerAdvanced Solid Tumors
Ensem Therapeutics233 enrolled10 locationsNCT06993844
Recruiting
Phase 1Phase 2

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Advanced Solid TumorsSCLCHRD Cancer
National Cancer Institute (NCI)120 enrolled1 locationNCT04826341
Recruiting
Phase 2

A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Advanced Solid TumorsHER2 Mutation
Bayer111 enrolled54 locationsNCT06760819
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1Phase 2

EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors

Endometrial CancerAdvanced Solid TumorsMSI-H or dMMR Advanced Solid Tumors+4 more
Eikon Therapeutics160 enrolled10 locationsNCT07262619
Recruiting
Phase 1Phase 2

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Non-small Cell Lung Cancer (NSCLC)Advanced Solid TumorsNSCLC+3 more
Revolution Medicines, Inc.370 enrolled1 locationNCT07397338
Recruiting
Phase 1Phase 2

Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Advanced Solid TumorsAdvanced or Metastatic KRAS-mutant Tumor in Pancreatic AdenocarcinomaAdvanced or Metastatic KRAS-mutant Tumor in Colorectal Cancer+2 more
Auricula Biosciences Inc.110 enrolled4 locationsNCT07148128
Recruiting
Phase 1Phase 2

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Advanced Solid Tumors
Bristol-Myers Squibb360 enrolled6 locationsNCT06730750
Recruiting
Phase 1Phase 2

Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors

Advanced Solid Tumors
Mainline Biosciences (Shanghai) Co., Ltd156 enrolled1 locationNCT06840821
Recruiting
Phase 1Phase 2

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumors
DualityBio Inc.862 enrolled107 locationsNCT05914116
Recruiting
Phase 1Phase 2

A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors

Advanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.260 enrolled1 locationNCT07208773
Recruiting
Phase 1Phase 2

Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

Non-small Cell Lung Cancer (NSCLC)Pancreatic Ductal Adenocarcinoma (PDAC)Advanced Solid Tumors+1 more
Revolution Medicines, Inc.754 enrolled16 locationsNCT05379985
Recruiting
Phase 1Phase 2

A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors

Advanced Solid Tumors
LigaChem Biosciences, Inc.300 enrolled8 locationsNCT05941507
Recruiting
Phase 1Phase 2

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

Breast CancerAdvanced Solid Tumors
MediLink Therapeutics (Suzhou) Co., Ltd.414 enrolled20 locationsNCT07169994
Recruiting
Phase 1Phase 2

A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Advanced Solid Tumors
Eikon Therapeutics130 enrolled10 locationsNCT06907043
Recruiting
Phase 1Phase 2

A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors

CholangiocarcinomaAdvanced Solid TumorsIntrahepatic Cholangiocarcinoma (Icc)+9 more
Cogent Biosciences, Inc.110 enrolled15 locationsNCT06777316
Recruiting
Phase 1Phase 2

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors

Advanced Solid TumorsCarcinomaNeoplasms+9 more
Marengo Therapeutics, Inc.365 enrolled32 locationsNCT05592626
Recruiting
Phase 1Phase 2

AK129 Combination Therapy for Advanced Solid Tumors

Head and Neck Squamous Cell Carcinoma (HNSCC)Advanced Solid TumorsColorectal Adenocarcinoma+1 more
Akeso230 enrolled1 locationNCT06943820
Recruiting
Phase 1Phase 2

TT-702 in Patients With Advanced Solid Tumours.

Advanced Solid Tumors
Cancer Research UK188 enrolled3 locationsNCT05272709